Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.

Richards KA, Liou JI, Cryns VL, Downs TM, Abel EJ, Jarrard DF.

J Urol. 2018 Jun 22. pii: S0022-5347(18)43412-X. doi: 10.1016/j.juro.2018.06.031. [Epub ahead of print]

PMID:
29940252
2.

Short-term methionine deprivation improves metabolic health via sexually dimorphic, mTORC1-independent mechanisms.

Yu D, Yang SE, Miller BR, Wisinski JA, Sherman DS, Brinkman JA, Tomasiewicz JL, Cummings NE, Kimple ME, Cryns VL, Lamming DW.

FASEB J. 2018 Jun;32(6):3471-3482. doi: 10.1096/fj.201701211R. Epub 2018 Jan 30.

PMID:
29401631
3.

Hypocalciuria as a Predictor of Reduced Intestinal Calcium Absorption.

Hanseree P, Staples AC, Cryns VL, Hansen KE.

J Endocr Soc. 2017 Aug 7;1(9):1179-1187. doi: 10.1210/js.2017-00234. eCollection 2017 Sep 1. Erratum in: J Endocr Soc. 2017 Nov 24;1(12 ):1506.

4.

Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.

Strekalova E, Malin D, Rajanala H, Cryns VL.

Breast Cancer Res Treat. 2017 Jun;163(3):435-447. doi: 10.1007/s10549-017-4201-0. Epub 2017 Mar 21.

PMID:
28324269
5.

αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis.

Voduc KD, Nielsen TO, Perou CM, Harrell JC, Fan C, Kennecke H, Minn AJ, Cryns VL, Cheang MCU.

NPJ Breast Cancer. 2015 Oct 21;1. pii: 15014. doi: 10.1038/npjbcancer.2015.14.

6.

GSK-3 inhibition overcomes chemoresistance in human breast cancer.

Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F, O'Halloran T, Cryns VL, Mazar AP.

Cancer Lett. 2016 Oct 1;380(2):384-92. doi: 10.1016/j.canlet.2016.07.006. Epub 2016 Jul 14.

7.

αB-crystallin and HspB2 deficiency is protective from diet-induced glucose intolerance.

Toft DJ, Fuller M, Schipma M, Chen F, Cryns VL, Layden BT.

Genom Data. 2016 May 13;9:10-7. doi: 10.1016/j.gdata.2016.03.010. eCollection 2016 Sep.

8.

αB-crystallin: Portrait of a malignant chaperone as a cancer therapeutic target.

Malin D, Petrovic V, Strekalova E, Sharma B, Cryns VL.

Pharmacol Ther. 2016 Apr;160:1-10. doi: 10.1016/j.pharmthera.2016.01.012. Epub 2016 Jan 25. Review.

9.

Esterase- and pH-responsive poly(β-amino ester)-capped mesoporous silica nanoparticles for drug delivery.

Fernando IR, Ferris DP, Frasconi M, Malin D, Strekalova E, Yilmaz MD, Ambrogio MW, Algaradah MM, Hong MP, Chen X, Nassar MS, Botros YY, Cryns VL, Stoddart JF.

Nanoscale. 2015 Apr 28;7(16):7178-83. doi: 10.1039/c4nr07443b.

PMID:
25820516
10.

Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.

Strekalova E, Malin D, Good DM, Cryns VL.

Clin Cancer Res. 2015 Jun 15;21(12):2780-91. doi: 10.1158/1078-0432.CCR-14-2792. Epub 2015 Feb 27.

11.

ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo.

Malin D, Strekalova E, Petrovic V, Rajanala H, Sharma B, Ugolkov A, Gradishar WJ, Cryns VL.

Oncogene. 2015 Nov 5;34(45):5626-34. doi: 10.1038/onc.2015.12. Epub 2015 Feb 16.

12.

NanoFlares for the detection, isolation, and culture of live tumor cells from human blood.

Halo TL, McMahon KM, Angeloni NL, Xu Y, Wang W, Chinen AB, Malin D, Strekalova E, Cryns VL, Cheng C, Mirkin CA, Thaxton CS.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17104-9. doi: 10.1073/pnas.1418637111. Epub 2014 Nov 17.

13.

pH and amphiphilic structure direct supramolecular behavior in biofunctional assemblies.

Moyer TJ, Finbloom JA, Chen F, Toft DJ, Cryns VL, Stupp SI.

J Am Chem Soc. 2014 Oct 22;136(42):14746-52. doi: 10.1021/ja5042429. Epub 2014 Oct 13.

14.

αB-crystallin: a novel regulator of breast cancer metastasis to the brain.

Malin D, Strekalova E, Petrovic V, Deal AM, Al Ahmad A, Adamo B, Miller CR, Ugolkov A, Livasy C, Fritchie K, Hamilton E, Blackwell K, Geradts J, Ewend M, Carey L, Shusta EV, Anders CK, Cryns VL.

Clin Cancer Res. 2014 Jan 1;20(1):56-67. doi: 10.1158/1078-0432.CCR-13-1255. Epub 2013 Oct 16.

15.

Photoexpulsion of surface-grafted ruthenium complexes and subsequent release of cytotoxic cargos to cancer cells from mesoporous silica nanoparticles.

Frasconi M, Liu Z, Lei J, Wu Y, Strekalova E, Malin D, Ambrogio MW, Chen X, Botros YY, Cryns VL, Sauvage JP, Stoddart JF.

J Am Chem Soc. 2013 Aug 7;135(31):11603-13. doi: 10.1021/ja405058y. Epub 2013 Jul 25.

16.

αB-crystallin promotes oncogenic transformation and inhibits caspase activation in cells primed for apoptosis by Rb inactivation.

Petrovic V, Malin D, Cryns VL.

Breast Cancer Res Treat. 2013 Apr;138(2):415-25. doi: 10.1007/s10549-013-2465-6. Epub 2013 Mar 8.

17.

Biotargeted nanomedicines for cancer: six tenets before you begin.

Goldberg MS, Hook SS, Wang AZ, Bulte JW, Patri AK, Uckun FM, Cryns VL, Hanes J, Akin D, Hall JB, Gharkholo N, Mumper RJ.

Nanomedicine (Lond). 2013 Feb;8(2):299-308. doi: 10.2217/nnm.13.3.

18.

Coassembled cytotoxic and pegylated peptide amphiphiles form filamentous nanostructures with potent antitumor activity in models of breast cancer.

Toft DJ, Moyer TJ, Standley SM, Ruff Y, Ugolkov A, Stupp SI, Cryns VL.

ACS Nano. 2012 Sep 25;6(9):7956-65. Epub 2012 Aug 28.

19.

Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin.

Soukasene S, Toft DJ, Moyer TJ, Lu H, Lee HK, Standley SM, Cryns VL, Stupp SI.

ACS Nano. 2011 Nov 22;5(11):9113-21. doi: 10.1021/nn203343z. Epub 2011 Nov 1.

20.

American journal of cancer research: editorial board (2011).

Antin JH, Aplin AE, Cheng SY, Emmert-Buck MR, Cryns VL, Wang D.

Am J Cancer Res. 2011;1(6):817-22. Epub 2011 Jun 28. No abstract available.

21.

Launching of American Journal of Cancer Research.

Antin JH, Emmert-Buck MR, Aplin AE, Cheng SY, Cryns VL, Wang D.

Am J Cancer Res. 2011;1(1):i. Epub 2010 Nov 5. No abstract available.

22.

Catechol polymers for pH-responsive, targeted drug delivery to cancer cells.

Su J, Chen F, Cryns VL, Messersmith PB.

J Am Chem Soc. 2011 Aug 10;133(31):11850-3. doi: 10.1021/ja203077x. Epub 2011 Jul 19.

23.

Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.

Malin D, Chen F, Schiller C, Koblinski J, Cryns VL.

Clin Cancer Res. 2011 Aug 1;17(15):5005-15. doi: 10.1158/1078-0432.CCR-11-0099. Epub 2011 Jun 8.

24.

Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.

Toft DJ, Cryns VL.

Mol Endocrinol. 2011 Feb;25(2):199-211. doi: 10.1210/me.2010-0164. Epub 2010 Sep 22. Review.

25.

Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy.

Lee SM, Ahn RW, Chen F, Fought AJ, O'Halloran TV, Cryns VL, Nguyen ST.

ACS Nano. 2010 Sep 28;4(9):4971-8. doi: 10.1021/nn100560p.

26.

A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer.

Ahn RW, Chen F, Chen H, Stern ST, Clogston JD, Patri AK, Raja MR, Swindell EP, Parimi V, Cryns VL, O'Halloran TV.

Clin Cancer Res. 2010 Jul 15;16(14):3607-17. doi: 10.1158/1078-0432.CCR-10-0068. Epub 2010 Jun 2.

27.

Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide.

Standley SM, Toft DJ, Cheng H, Soukasene S, Chen J, Raja SM, Band V, Band H, Cryns VL, Stupp SI.

Cancer Res. 2010 Apr 15;70(8):3020-6. doi: 10.1158/0008-5472.CAN-09-3267. Epub 2010 Mar 30.

28.

The small heat shock protein HspB2 is a novel anti-apoptotic protein that inhibits apical caspase activation in the extrinsic apoptotic pathway.

Oshita SE, Chen F, Kwan T, Yehiely F, Cryns VL.

Breast Cancer Res Treat. 2010 Nov;124(2):307-15. doi: 10.1007/s10549-010-0735-0. Epub 2010 Jan 20.

29.

Induction of the small heat shock protein alphaB-crystallin by genotoxic stress is mediated by p53 and p73.

Evans JR, Bosman JD, Brown-Endres L, Yehiely F, Cryns VL.

Breast Cancer Res Treat. 2010 Jul;122(1):159-68. doi: 10.1007/s10549-009-0542-7. Epub 2009 Sep 24.

30.

Regulation of alphaB-crystallin gene expression by the transcription factor Ets1 in breast cancer.

Bosman JD, Yehiely F, Evans JR, Cryns VL.

Breast Cancer Res Treat. 2010 Jan;119(1):63-70. doi: 10.1007/s10549-009-0330-4. Epub 2009 Feb 11.

31.

Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.

Lu M, Strohecker A, Chen F, Kwan T, Bosman J, Jordan VC, Cryns VL.

Clin Cancer Res. 2008 May 15;14(10):3168-76. doi: 10.1158/1078-0432.CCR-07-4362.

32.

Caspase cleavage of HER-2 releases a Bad-like cell death effector.

Strohecker AM, Yehiely F, Chen F, Cryns VL.

J Biol Chem. 2008 Jun 27;283(26):18269-82. doi: 10.1074/jbc.M802156200. Epub 2008 Apr 17.

33.

AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas.

Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV, Watkin WG, Wiley EL, Cryns VL, Diaz LK.

Ann Diagn Pathol. 2008 Feb;12(1):33-40. doi: 10.1016/j.anndiagpath.2007.02.004. Epub 2007 Oct 24.

PMID:
18164413
34.

Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.

Diaz LK, Cryns VL, Symmans WF, Sneige N.

Adv Anat Pathol. 2007 Nov;14(6):419-30. Review.

PMID:
18049131
35.

alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.

Ivanov O, Chen F, Wiley EL, Keswani A, Diaz LK, Memmel HC, Rademaker A, Gradishar WJ, Morrow M, Khan SA, Cryns VL.

Breast Cancer Res Treat. 2008 Oct;111(3):411-7. Epub 2007 Oct 30.

PMID:
17968656
36.

Caspase proteolysis of the integrin beta4 subunit disrupts hemidesmosome assembly, promotes apoptosis, and inhibits cell migration.

Werner ME, Chen F, Moyano JV, Yehiely F, Jones JC, Cryns VL.

J Biol Chem. 2007 Feb 23;282(8):5560-9. Epub 2006 Dec 18.

37.

Plakoglobin deficiency protects keratinocytes from apoptosis.

Dusek RL, Godsel LM, Chen F, Strohecker AM, Getsios S, Harmon R, Müller EJ, Caldelari R, Cryns VL, Green KJ.

J Invest Dermatol. 2007 Apr;127(4):792-801. Epub 2006 Nov 16.

38.

Deconstructing the molecular portrait of basal-like breast cancer.

Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL.

Trends Mol Med. 2006 Nov;12(11):537-44. Epub 2006 Sep 29. Review.

PMID:
17011236
39.

Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo.

Guillozet-Bongaarts AL, Cahill ME, Cryns VL, Reynolds MR, Berry RW, Binder LI.

J Neurochem. 2006 May;97(4):1005-14. Epub 2006 Apr 5.

40.

AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer.

Moyano JV, Evans JR, Chen F, Lu M, Werner ME, Yehiely F, Diaz LK, Turbin D, Karaca G, Wiley E, Nielsen TO, Perou CM, Cryns VL.

J Clin Invest. 2006 Jan;116(1):261-70.

41.

The differentiation-dependent desmosomal cadherin desmoglein 1 is a novel caspase-3 target that regulates apoptosis in keratinocytes.

Dusek RL, Getsios S, Chen F, Park JK, Amargo EV, Cryns VL, Green KJ.

J Biol Chem. 2006 Feb 10;281(6):3614-24. Epub 2005 Nov 14.

42.

Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.

Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.

Cancer Res. 2005 Jun 1;65(11):4799-808.

43.

The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3.

Kamradt MC, Lu M, Werner ME, Kwan T, Chen F, Strohecker A, Oshita S, Wilkinson JC, Yu C, Oliver PG, Duckett CS, Buchsbaum DJ, LoBuglio AF, Jordan VC, Cryns VL.

J Biol Chem. 2005 Mar 25;280(12):11059-66. Epub 2005 Jan 14.

45.

Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest.

Lu M, Kwan T, Yu C, Chen F, Freedman B, Schafer JM, Lee EJ, Jameson JL, Jordan VC, Cryns VL.

J Biol Chem. 2005 Feb 25;280(8):6742-51. Epub 2004 Nov 29.

46.

Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease.

Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, Bennett DA, Cryns VL, Berry RW, Binder LI.

J Neurosci. 2004 Sep 8;24(36):7895-902.

47.

Proteolysis of the mismatch repair protein MLH1 by caspase-3 promotes DNA damage-induced apoptosis.

Chen F, Arseven OK, Cryns VL.

J Biol Chem. 2004 Jun 25;279(26):27542-8. Epub 2004 Apr 15.

48.

Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease.

Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL.

Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10032-7. Epub 2003 Jul 29.

49.

Crucial role of the specificity-determining loop of the integrin beta4 subunit in the binding of cells to laminin-5 and outside-in signal transduction.

Tsuruta D, Hopkinson SB, Lane KD, Werner ME, Cryns VL, Jones JC.

J Biol Chem. 2003 Oct 3;278(40):38707-14. Epub 2003 Jul 16.

50.

Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment.

Berry RW, Abraha A, Lagalwar S, LaPointe N, Gamblin TC, Cryns VL, Binder LI.

Biochemistry. 2003 Jul 15;42(27):8325-31.

PMID:
12846581

Supplemental Content

Support Center